Skip to Content

Notice

Government-Owned Inventions; Availability for Licensing

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

National Institutes of Health, Public Health Service, HHS.

ACTION:

Notice.

SUMMARY:

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES:

Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Use of Razoxane for the Treatment of Alzheimer's Disease

Description of Technology: Abnormalities in the metabolism of the transition metals, iron and copper, have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Excessive iron accumulation in the brain occurs in both AD and PD. High levels of reactive iron can increase oxidative stress-induced neuronal vulnerability, increase the toxicity of environmental or endogenous toxins, and accelerate hallmark pathologies of these diseases.

As an example among many, the expression level of amyloid-β precursor protein (APP) that generates the AD neurotoxic peptide, amyloid-β (Aβ), is Start Printed Page 53429regulated in large part by iron levels. APP mRNA has an iron response element (IRE) in its 5′-untranslated region, and cleavage of APP to release different amyloidogenic and non-amyloidogenic peptide forms involves metalloproteases.

Elevated Aβ levels as well as plaques formed by aggregation of Aβ involve iron, and play a significant role in degeneration of the brain seen in AD. Chelators can reduce both the generation and aggregation of Aβ. Razoxane, a bisdioxopiperazine, is an orally active metal chelator approved for the treatment of cancer, where it and dexrazoxane have been effectively used for decades. In neuronal cell culture models, razoxane induced dose-dependent reductions in APP and Aβ levels without toxicity. In animal experiments (transgenic mice expressing human Aβ), razoxane substantially reduced Aβ 1-40 and 1-42 in brain by up to 46% without toxicity following once daily, 21 day administration.

The claimed invention is the novel use of razoxane and other bisdioxopiperazines to reduce amyloid-beta peptide levels, reduce aggregation of alpha-synuclein and tau protein, and reduce abnormal protein folding or aggregation for the treatment of AD and related diseases with protein aggregation pathology. Since razoxane has been approved for humans use, it could be more quickly developed as a treatment for AD, PD and other diseases.

Market:

  • Up to 4.5 million Americans are estimated to suffer from AD, which usually strikes after the age of 60.
  • Population longevity is increasing so AD is expected to be a growing health problem.
  • Currently marketed drugs only delay the severity of AD so better solutions are needed.

Development Status: Clinical safety data and pre-clinical efficacy data for treatment of Alzheimer's disease.

Inventors: Nigel H. Greig (NIA).

Patent Status:

  • U.S. Provisional Application No. 60/811,836 filed 08 Jun 2006 (HHS Reference No. E-216-2007/0-US-01).
  • PCT Application No. PCT/US2007/013607 filed 08 Jun 2007, which published as WO 2007/146178 on 21 Dec 2007 (HHS Reference No. E-216-2007/0-PCT-02).

Licensing Status: Available for exclusive or non-exclusive licensing.

Licensing Contact: Norbert Pontzer, J.D., PhD; 301-435-5502; pontzern@mail.nih.gov.

Collaborative Research Opportunity: The National Institute on Aging, Laboratory of Neurosciences, Section on Drug Design & Development, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize razoxane and analogues for the treatment of neurodegenerative disorders, such as Alzheimer's and Parkinson's diseases. Please contact Nigel H. Greig (Greign@grc.nia.nih.gov) for more information.

Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

Description of Technology: The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood vessels where E-selectin is normally expressed by the localized production of immunosuppressive cytokines, modulating the actions of otherwise pro-inflammatory T-cells that can aberrantly cause demyelination of neurons, which leads to diseases like MS.

Applications: In addition to MS, potentially effective in treating other autoimmune disorders such as rheumatoid arthritis, type 1 diabetes, psoriasis, and those that affect blood vessels.

Market: MS may affect more than 2.5 million people worldwide. Currently, it is estimated that approximately 400,000 Americans are afflicted with MS and 200 more are diagnosed weekly.

Development Status: In vitro and in vivo data are available.

Inventors: Jacqueline Shukaliak-Quandt et al. (NINDS).

Patent Status:

  • U.S. Provisional Application No. 60/828,735 filed 09 Oct 2006 (HHS Reference No. E-153-2005/0-US-01).
  • PCT Application No. PCT/2007/021682 filed 09 Oct 2007 (HHS Reference No. E-153-2005/2-PCT-02).

Licensing Status: Available for non-exclusive or exclusive licensing.

Licensing Contact: Norbert Pontzer, J.D., PhD; 301-435-5502; pontzern@mail.nih.gov.

Use of Pentosan Polysulfate To Treat Certain Conditions of the Prostate

Description of Technology: Benign prostatic hyperplasia (BPH), involving a proliferation of smooth muscle cells and increased deposition of extracellular matrix, is a common development: 50% of men over age 60 (about 12.5 million men), and as much as 80% of all men over age 80 (about 3.2 million men), have some enlargement of the prostate gland.

This technology is a method for treating BHP using the oral medication, pentosan polysulfate. Pentosan polysulfate is a well known semi-synthetic polysaccharide extracted from beech wood cellulose that is FDA approved for the treatment of interstitial fibrosis. The current technology builds on the surprising discovery that pentosan polysulfate can cause regression of scarring and lesions in prostatic tissue. Pentosan polysulfate reduces or eliminates both smooth muscle cell proliferation and extracellular matrix deposition, and thus reduces the size of the prostate gland and associated obstructive symptoms.

Applications and Advantages:

  • A method of treating benign prostatic hyperplasia using pentosan polysulfate.
  • The method treats the underlying pathology of BHP non-invasively.
  • The method addresses associated conditions, such as chronic prostatitis, prostadynia, and irritative bladder conditions (other than interstitial cystitis).
  • Pentosan polysulfate has been FDA approved for another use.

Development Status: In vitro studies on BPH biopsy samples that demonstrate the drug slows the growth of prostate cells and extracellular matrix have been completed.

Patent Status: U.S. Patent No. 6,828,309 issued 07 Dec 2004 (HHS Reference No. E-104-1997/0-US-03).

Inventor: Gary E. Striker (NIDDK).

Publication: SJ Elliot et al. Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. Prostate Cancer Prostatic Dis. 2003;6(2):138-142.

Licensing Status: Available for licensing.

Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521; Fatima.Sayyid@nih.hhs.gov.

Start Signature

Dated: September 9, 2008.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

End Signature End Preamble

[FR Doc. E8-21504 Filed 9-15-08; 8:45 am]

BILLING CODE 4140-01-P